Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed director
Fibrocell Science, Inc. (FCSC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2019 8-K Quarterly results
05/15/2019 8-K Quarterly results
Docs: "Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights",
"Corporate Presentation May 15, 2019"
03/27/2019 8-K Quarterly results
Docs: "Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007",
"Corporate Presentation March 27, 2019"
11/13/2018 8-K Quarterly results
Docs: "Costs for the FCX-013",
"Corporate Presentation November 13, 2018"
08/09/2018 8-K Quarterly results
Docs: "Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights",
"Corporate Presentation August 9, 2018"
05/10/2018 8-K Quarterly results
Docs: "Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights",
"Corporate Presentation May 10, 2018"
03/19/2018 8-K Quarterly results
Docs: "Company to Host Conference Call and Webcast Today",
"Private Securities Litigation Reform Act of 1995. All"
11/13/2017 8-K/A Quarterly results
Docs: "Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - EXTON, PA - November 13, 2017 - Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the third quarter ended September 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EST. “The third quarter of 2017 was highlighted by encouraging interim results for the first cohort of adult patients dosed in the Phase 1/2 clinical trial of FCX-007, our product candidate for the treatment of recessive dystrophic epidermolysis bullosa , a devastating genetic skin dis..."
11/13/2017 8-K Quarterly results
Docs: "Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - EXTON, PA - November 13, 2017 - Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the third quarter ended September 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EST. “The third quarter of 2017 was highlighted by encouraging interim results for the first cohort of adult patients dosed in the Phase 1/2 clinical trial of FCX-007, our product candidate for the treatment of recessive dystrophic epidermolysis bullosa , a devastating genetic skin dis..."
08/09/2017 8-K Investor presentation, Quarterly results
Docs: "Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA - August 9, 2017 - Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “During the second quarter of 2017, we achieved important milestones that continue to advance the development of our gene therapy candidates for the treatment of rare and devastating diseases of the skin and connective tissue with high unmet needs,” said John Maslowski, President and Ch...",
"Corporate Presentation"
05/10/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Fibrocell Science, Inc. Selected Financial Information Consolidated Statements of Operations Three months ended September 30, 2015 Three months ended September 30, 2014 Nine months ended September 30, 2015 Nine months ended September 30, 2014 Revenue from product sales $ 49 $ 20 $ 217 $ 124",
"Corporate Presentation"
08/06/2015 8-K Quarterly results
Docs: "Fibrocell Science Reports Second Quarter 2015 Financial Results and Operational Highlights - Company to Host Conference Call and Webcast, Today at 8:30 a.m. EDT - EXTON, PA - August 6, 2015 - Fibrocell Science, Inc. , an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2015 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “We’ve made significant progress advancing our pipeline,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell. “Submission of an IND application for FCX-007-our lead orphan gene-therapy product candidate fo..."
03/13/2015 8-K Quarterly results
Docs: "Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results"
11/07/2014 8-K Quarterly results
Docs: "Fibrocell Science Reports Third Quarter and Nine Month 2014 Financial and Operating Results"
08/11/2014 8-K Quarterly results
Docs: "Fibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating Results"
05/19/2014 8-K Quarterly results
Docs: "Fibrocell Science Reports First Quarter 2014 Financial and Operating Results"
03/17/2014 8-K Quarterly results
Docs: "Fibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating Results - Company to Host Conference Call and Webcast at 8:30 a.m. EDT, Today, March 17, 2014 -"
11/14/2013 8-K Quarterly results
Docs: "Fibrocell Science Announces Third Quarter 2013 Financial Results"
03/16/2006 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy